Drugs / PD-L1/IDO Peptide Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05843448 | Apr 2023 → Mar 2026 overdue | bladder carcinoma in situ | University of California, Davis | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD-L1/IDO Peptide Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05843448 ↗ |
| Action | Activate | “It is designed to activate the patient's own immune cells (called T-cells) to fight the tumor” NCT05843448 ↗ |
| Modality | Vaccine | “PD-L1/IDO peptide vaccine” NCT05843448 ↗ |
| Route | Subcutaneous | “PD-L1/IDO peptide vaccine subcutaneously (SC)” NCT05843448 ↗ |